1. HIGH RATE OF MORBID CENTRAL LINE ASSOCIATED COMPLICATIONS DURING TREATMENT WITH DOSE‐ADJUSTED R‐EPOCH THERAPY FOR NON‐HODGKIN LYMPHOMA. (June 2017) Authors: Reagan, P.; David, R.; Baran, A.; Kelly, J.; Loh, K.; Casulo, C.; Barr, P.; Friedberg, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (23rd June 2022) Authors: Ryan, C.; Brander, D.; Barr, P.; Tyekucheva, S.; Ren, Y.; Hackett, L.; McDonough, M.; Pena Del Aguila, K.; McEwan, M.; Collins, M.; Abramson, J.; Jacobsen, E.; LaCasce, A.; Fisher, D.; Brown, J.; Davids, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 572 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗